FDA drafts adaptive clinical trial design guidance

By Nick Taylor

- Last updated on GMT

Related tags Clinical trial

The FDA’s draft guidance on adaptive design in clinical trials is a balanced, practical publication, according to the EVP of a CRO who expects the document to generate a “robust discussion”.

Adaptive designs have been identified as methods for improving the efficiency of the clinical trial process but there are concerns that some techniques can lead to bias. These concerns were highlighted in a recent paper in the Journal of the American Medical Association​.

To help companies and regulatory agencies navigate this emerging area the US Food and Drug Administration (FDA) has drafted guidance​ which discusses the clinical, statistical and regulatory aspects of various adaptive design studies.

Speaking to Outsourcing-Pharma, Jim Higgins, executive vice president (EVP) and director of biometrics at Health Decisions, said the document is balanced and contains a lot of practical information.

This could help to reduce confusion and allow pharma and contract research organisations (CRO) to embrace certain acceptable methods. Well understood adaptive designs covered by the draft include group sequential methods, which Higgins believes are “nicely clarified​”.


Higgins explained that adaptive design is a well debated topic in the statistics and clinical research communities and he anticipates this will lead to a “robust discussion​” of the draft.

The only comment on the draft so far has come from William Rosenberger, professor and chair, department of statistics, George Mason University, Virginia, US, who said the “document is remarkably narrow for such an important topic​”.

Higgins believes the document’s scope is deliberate, with the FDA choosing to focus on the better understood basics before branching out to other areas in the future.

The comment period closes on June 1.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more